Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: A new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 793-799

  Mavroudis, D A ^a   Jiang, Y Z ^a   Hensel, N ^a   Lewalle, P ^a   Couriel, D ^a   Kreitman, R J ^b   Pastan, I ^b   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alloreactivity; GVHD; Haploidentical; Immunotoxin; Specific depletion

Indexed keywords

IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; ARTICLE; BONE MARROW TRANSPLANTATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; BONE MARROW TRANSPLANTATION; COLONY-FORMING UNITS ASSAY; EXOTOXINS; GRAFT VS HOST DISEASE; HAPLOTYPES; HUMANS; IMMUNOTOXINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VIRULENCE FACTORS;

EID: 0029922689     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
2. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia New Engl J Med 1986; 314: 729-735.
3. Beatty PG. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992; 19: 13-19.
4. Poynton CH. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988; 3: 265-279.
5. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185-192.
6. Marmont AM, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
7. Ash RC, Horowitz MM, Gale RP et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991; 7: 443-152.
8. Bozdech MJ, Sondel PM, Trigg ME et al. Transplantation of HLA-haploidentical T cell depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985; 13: 1201-1210.
9. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulatng factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
10. Daley JP, Rozans MK, Smith BR et al. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. Blood 1987; 70: 960-964.
11. Shapiro RS, McClain K, Frizzera G. et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
12. DeGast GC, Gratama JW, Verdonck LF et al. The influence of T cell depletion on recovery of T cell proliferation to herpes viruses and candida after allogeneic bone marrow transplantation. Transplantation 1989; 48: 111-115.
13. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
14. Komgold R, Sprent J. T cell subsets in graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graftvs-Host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 31-50.
15. Kreitman RJ, Pastan I. Recombinant toxins. Adv Pharmacol 1994; 28: 193-219.
16. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma 1994; 13: 1-10.
17. Kreitman RJ, Ballon P, Chaudhary VK et al. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 1994; 83: 426-434.
18. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted IL-4 toxin in mice with IL-4 receptor bearing human carcinoma. Cancer Res 1995; 55: 3357-3363.
19. Kreitman RJ, FitzGerald DJ, Pastan I. New antileukemic agents: recombinant immunotoxins. In: Atkinson K (ed). Clinical Bone Marrow Transplantation. Cambridge University Press. Cambridge, 1994, pp 623-628.
20. Spence C, Nachman M, Gately MK et al. Affinity purification and characterization of anti-Tac(Fv)PE38KDEL: a highly potent cytotoxic agent specific to cells bearing IL-2 receptors. Bioconjug Chem 1993; 4: 63-68.
21. Chaudhary VK, Queen C. Junghans RP et al. A recombinant immunotoxin consisting of two antibody variable domains fused to pseudomonas exotoxin. Nature 1989; 339: 394-395.
22. 1(Fv)-PE40. a recombinant immunotoxin cytotoxic toward cells bearing the β-chain of the IL-2 receptor. J Immunology 1992; 149: 2810-2815.
23. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA 1994; 91: 6889-6893.
24. Brinkmann U, Buchner J, Pastan I. Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. Proc Nail Acad Sci USA 1992; 89: 3075-3079.
25. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 1990; 87: 308-312.
26. Henslee-Downey PJ. Mismatched bone marrow transplantation. Curr Opin Oncol 1995; 7: 115-121.
27. Naparstek E, Nagler A, Cividalli G et al. T cell-depleted allogeneic BMT for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
28. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
29. Datta AR, Barrett AJ. Jiang YZ et al. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14: 517-524.
30. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355-361.
31. Mickelson EM, Anasetti S, Yoon Choo GM et al. Role of the mixed lymphocyte culture reaction in predicting acute GVHD after marrow transplants from haploidentical and unrelated donors. Transplant Proc 1993; 25: 1239-1240.
32. Cavazzana-Calvo M, Fromont C, Le Deist F et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50: 1-7.
33. Tazzan PL, Bolognesi A, De Totero D et al. B-B10 (anti-CD25)-saporin immunotoxin: a possible tool in graft-versushost disease treatment. Transplantation 1992; 54: 351-356.
34. Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in a H-2 haplotype disparate mouse combination. Blood 1994; 83: 288-298.